Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax (NASDAQ:NVAX) shares climbed ~35% in the premarket on Thursday after the COVID-19 vaccine maker lifted its full-year ...

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of $2.93. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...

Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) ...

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...